ARTICLE | Clinical News
Bendamustine RTD regulatory update
April 20, 2015 7:00 AM UTC
FDA accepted for review an NDA for EP-3102 to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with ...